n3m3sis
7 años hace
LED Medical Diagnostics Announces Consolidation of Shares on 10 for 1 Basis
VANCOUVER, BC / ACCESSWIRE / November 29, 2017 / LED Medical Diagnostics Inc. ("LED" or the "Company") (TSX-V: LMD; OTCQB: LEDIF; FSE: LME) is pleased to announce that the TSX Venture Exchange has approved the consolidation of its common shares on a 10 for 1 basis. The consolidation will take effect at the open of market on Thursday, November 30, 2017. Assuming no other change in the issued capital of the Company, it is expected that upon completion of the consolidation LED will have approximately 37,914,637 common shares issued and outstanding, reduced from 379,146,372 common shares that are currently issued and outstanding.
At the open of market on Thursday, November 30, 2017, the CUSIP number for the common shares of LED will change to 50184T406, however the Company's trading symbol and name will not change. No fractional common shares will be issued and no cash will be paid in lieu of fractional, post-consolidation common shares. The number of post-consolidation common shares to be received by a shareholder will be rounded such that a fractional share of less than one-half of a share will be rounded down to the nearest whole number and a fractional share of one-half or more will be rounded up to the nearest whole number.
Dr. David Gane, CEO of LED Medical Diagnostics, stated: "The increased share price post consolidation is expected to make LED more attractive to institutional investors and easier to do business with Dental Support Organizations clients and other corporate customers for our unique offering of imaging products and services. It will also more accurately reflect the size and potential of our business."
About LED Medical Diagnostics
LED Medical Diagnostics Inc. is a dental imaging technology provider focused on delivering state-of-the-art imaging software and systems. Through its wholly-owned subsidiaries LED Dental Inc., LED Dental Ltd., and Apteryx, Inc., LED Medical has provided dentists and oral health specialists with advanced diagnostic imaging products and software for over 20 years. LED's proprietary technologies include the VELscope Vx Enhanced Oral Assessment and TUXEDO Intraoral Sensors, in addition to Apteryx's XrayVision, XVWeb and XrayVision DCV imaging software solutions.
Backed by an experienced leadership team and dedicated to a higher level of service and support, LED is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio. The Company is currently listed on the TSXV under the symbol LMD, the OTCQB under the symbol LEDIF, as well as the Frankfurt Stock Exchange under the symbol LME.
Read more: http://www.digitaljournal.com/pr/3579605#ixzz4zvepOocJ
Chaka
7 años hace
Market Value1 $22,430,032 a/o Oct 16, 2017
Authorized Shares 373,833,872 a/o Sep 20, 2017
Outstanding Shares 373,833,872 a/o Sep 20, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 373,833,872 a/o Sep 20, 2017
------------------------------
Isn't it kinda odd float, OS, and AS same #s?
Thoughts?
Tia.
Chaka
n3m3sis
7 años hace
Dental Care Alliance Selects LED Medical Diagnostics Subsidiaries LED Dental and Apteryx, Inc. as Preferred Imaging Technology Providers
Read more at http://www.stockhouse.com/news/press-releases/2017/10/02/dental-care-alliance-selects-led-medical-diagnostics-subsidiaries-led-dental#tqLSBPIbrzhldZya.99
V.LMD, V.LME | 4 hours ago
Dental Care Alliance Selects LED Medical Diagnostics Subsidiaries LED Dental and Apteryx, Inc. as Preferred Imaging Technology Providers
Dental Care Alliance Moves Forward with Integration of Apteryx XrayVision Software and LED Dental Imaging Devices Across Their Network of Practices
Vancouver, British Columbia (FSCwire) - LED Medical Diagnostics Inc. ("LED" or the "Company") (TSX-V: LMD) is pleased to announce that Dental Care Alliance (DCA) has selected the Company’s wholly-owned subsidiaries, LED Dental and Apteryx, Inc., as their preferred providers for dental imaging devices and software technologies.
Established in 1991, Dental Care Alliance is committed to the improvement of patient care through innovative practice-support solutions. DCA is one of the United States’ largest and oldest dental support organizations, with 265 affiliated practices across all dental specialties in 13 states. Dentists affiliated with Dental Care Alliance are free to focus on patient care without the encumbrances of business management or making large capital investments. DCA has made a commitment to providing cutting edge diagnostic and treatment planning technologies that are essential for delivering exceptional care for their patients.
“The combination of Apteryx and LED Dental imaging technologies provides our team with solutions that meet the unique needs of dental support organizations,” stated Mitch Olan, Executive Chairman of Dental Care Alliance. “Apteryx’s XrayVision software is not only a great image management and analysis system, but it also allows us flexibility in how we address aging imaging technologies across our organization. XrayVision allows us to continue utilizing existing imaging systems, while smoothly transitioning to LED Dental technologies as upgrades are needed.”
LED Dental offers a comprehensive portfolio of dental imaging devices, including TUXEDO Intraoral Sensors, the VELscope Enhanced Oral Assessment, 3Shape TRIOS intraoral scanners and the RAYSCAN Alpha pan/ceph/CBCT. Dental Care Alliance will be investing in LED Dental imaging solutions moving forward for new locations and as existing technologies fail or require an upgrade in established practices.
Apteryx, Inc. is a leading developer of dental imaging software technologies, placing an emphasis on their open-architecture infrastructure that seamlessly integrates with a wide variety of imaging devices and practice management software systems. Apteryx was acquired by LED Medical Diagnostics in early 2017, becoming a sister company to LED Dental. The synergy between Apteryx and LED provides a one-stop solution that is uniquely suited to address the needs of any size practice, from single practitioners to large, multi-location dental service organizations and government enterprises.
“We are proud to be working with Dental Care Alliance to provide them with our end-to-end imaging solution,” remarked Lamar Roberts, President of LED and Apteryx. “Apteryx provides a unique offering in the industry, which delivers an exceptional budget and infrastructure advantage for DSO groups. The ability to utilize existing imaging devices without the need to purchase new equipment upfront allows investments in new technologies to be spread out over a period of time as older systems fail. When it is time to upgrade, we provide a single point of contact for sales and imaging support, so we can ensure that our customers’ software and imaging systems are all operating at peak performance.”
For more information on Dental Care Alliance, visit www.dentalcarealliance.net. For more information on LED, Apteryx and group practice/DSO partnerships, visit www.leddental.com or call 813.230.5819.
About LED Medical Diagnostics
LED Medical Diagnostics Inc. is a dental imaging technology provider focused on delivering state-of-the-art imaging software and systems. Through its wholly-owned subsidiaries LED Dental Inc., LED Dental Ltd., and Apteryx, Inc., LED Medical has provided dentists and oral health specialists with advanced diagnostic imaging products and software for over 20 years. LED’s proprietary technologies include the VELscope Vx Enhanced Oral Assessment and TUXEDO Intraoral Sensors, in addition to Apteryx’s XrayVision, XVWeb and XrayVision DCV imaging software solutions.
Backed by an experienced leadership team and dedicated to a higher level of service and support, LED is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio. The Company is currently listed on the TSX-V under the symbol LMD, the OTCQB under the symbol LEDIF, as well as the Frankfurt Stock Exchange under the symbol LME.
About Dental Care Alliance
Established in 1991 by Dr. Steven R. Matzkin, Dental Care Alliance’s success is the result of our unwavering commitment to improving the wellbeing of both patients and dentists through innovative and proven practice-support solutions. DCA-affiliated dentists join a family of more than 600 like-minded dentists and a support team of industry experts working together to advance dental service without compromising patient care.
As one of the country’s largest and oldest dental support organizations, DCA has 265 affiliated practices in 13 states, encompassing all facets of general dentistry and all recognized dental specialties. As a result, we offer dental professionals groundbreaking career and affiliation opportunities.
Investor Relations:
Bristol Capital
Glen Akselrod
Phone: 905.326.1888, ext. 10
Email: glen@bristolir.com
Media Contact:
LED Dental
Chris Koch
Phone: 678.293.9413
Email: chris.koch@leddental.com
Corporate Contact:
LED Medical
David Gane, CEO
Phone: 604.434.4614 x227
Email: david.gane@leddental.com
Read more at http://www.stockhouse.com/news/press-releases/2017/10/02/dental-care-alliance-selects-led-medical-diagnostics-subsidiaries-led-dental#tqLSBPIbrzhldZya.99
source
hammertime69
12 años hace
Chicago ENT Head and Neck Surgeons Using VELscope Vx to Enhance Oral Cancer Surgery Success Rate
Technology helps surgeons see cancerous and precancerous tissue not apparent to the naked eye
BURNABY, BRITISH COLUMBIA — JANUARY 9, 2013 — LedMedical Diagnostics Inc. (TSX.V: LMD) subsidiary LED Dental announced today that its VELscope Vx enhanced oral assessment device will now be used by Chicago Otolaryngology Associates for oral mucosal abnormality assessment and when performing surgery on oral cancer patients.
According to Chicago Otolaryngology Associates’ Howard Kotler, MD, FACS, “We pride ourselves on embracing state-of-the-art technologies that allow us to provide the best patient care possible. The VELscope Vx may significantly enhance our ability to see the entire cancerous or precancerous lesion that needs to be excised, allowing us to minimize risk of additional unnecessary surgery.”
The VELscope Vx’s fluorescence visualization technology is the first approved by the FDA and Health Canada to help surgeons determine the surgical margins when excising cancerous and precancerous tissues. The technology is also approved to help dental and medical professionals discover cancerous and precancerous tissue that might not be apparent to the unaided eye.
The vast majority of the nearly 12,000 VELscope devices in use around the world are used by dental practices. Typically, when a suspicious lesion is detected by a dentist, the patient is referred to an oral surgeon or a periodontist for a surgical biopsy, which is then evaluated by an oral pathologist. If the biopsy sample is determined to be cancerous or precancerous, the patient is usually referred to an ENT head and neck surgeon for consultation and likely excision. VELscope technology was developed to address the problem of detecting all abnormal tissue, including that beneath the surface, as well as making it possible for dentists to discover early stage oral cancer, which requires less invasive treatment and has a significantly higher chance of survival than when the disease is detected in late stages.
“We applaud Dr. Kotler and Chicago Otolaryngology Associates for being one of the first Otolaryngology practices in the U.S. to incorporate VELscope’s potentially life-saving technology,” said Peter Whitehead, founder and CEO of LED Dental and its parent, LED Medical Diagnostics Inc. (TSX-V: LMD).
Robert Cartagena, chief operating officer of VELscope Vx distributor DenMat Holdings, LLC, added, “We encourage Chicago-area dental practices, particularly those using VELscope technology, to consider Chicago Otolaryngology Associates when referring any patients who have a suspicious abnormality.” He noted that Chicago Otolaryngology Associates, which is based in Chicago’s Mercy Hospital and Medical Center, offers the convenience of a central Metro Chicago location.
About LED Medical Diagnostics Inc.
LED Medical Diagnostics Inc. was founded in 2003 and is headquartered in Burnaby, British Columbia, Canada. Its wholly-owned subsidiary, LED Dental Inc., is the manufacturer of the VELscope Vx enhanced oral assessment system. VELscope Vx devices, the first to apply tissue fluorescence visualization technology to the oral cavity, are used to conduct more screenings for oral cancer and other oral diseases than any adjunctive device in the world. For more information, call +1 (604) 434-4614, or visit www.velscope.com.
About the VELscope Vx
The VELscope Vx is a powerful FDA- and Health Canada-approved tool used to screen for oral cancer. It saves lives by helping detect early stage oral cancer and pre-cancer and other abnormalities in the mouth such as viral, fungal and bacterial infections. The VELscope Vx is distributed in over 20 countries by its exclusive global distributor, DenMat Holdings. For more information please call +1 (604) 434-4614, or visit www.velscope.com.
About DenMat
DenMat manufactures a broad range of cosmetic and restorative solutions as well as innovative small equipment devices, available in the U.S. and over 68 countries worldwide. Recently, DenMat became the exclusive distributor of the VELscope Vx®, the world’s leading adjunctive oral cancer screening device. In addition to award-winning products, DenMat also offers a wide array of continuing education programs, including Destination Education events. For more information, call +1-800-445-0345 or visit www.denmat.com.
Contact:
LED Medical Diagnostics Inc.
Mark Komonoski, Investor Relations
(403) 255-8483 or Toll-Free: (877) 255-8483
Cell: (403) 470-8384
mark@komonoski.com
Skype: mkomonoski
hammertime69
12 años hace
New Scientific Review Cites Critical Need for
Adjunctive Oral Cancer Screening Devices
VELscope® Vx from LED Medical Diagnostics Ltd. is the World’s
Leading Adjunctive Screening Device for Oral Cancer
BURNABY, British Columbia - January 29, 2013 - LED Medical Diagnostics Inc. (“LED Medical” or “the company”), a developer of LED-based tissue visualization technologies for the medical industry, announced today that a recent scientific review in the highly respected publication, The Journal of the American Dental Association, underscores the need for adjunctive screening technologies to help detect oral cancer and pre-cancer in earlier stages.
In a feature research article of the December 2012 issue of The Journal of the American Dental Association titled “The Limitations of the Clinical Oral Examination in Detecting Dysplastic Oral Lesions and Oral Squamous Cell Carcinoma”, authors Joel B. Epstein, Pelin Güneri, Hayal Boyacioglu and Elliot Abt conducted a systematic review of the effectiveness of the clinical oral examination (COE). The abstract can be downloaded at
http://jada.ada.org/content/143/12/1332.abstract
The COE is the conventional procedure taught in dental and hygiene schools to screen patients for oral cancer and other oral disease. It normally consists of a visual inspection of oral tissue, or oral mucosa, under incandescent or halogen light using the naked eye to look for suspicious lesions, as well as palpation of the face and neck to feel for suspicious lumps. The authors conclude, “The fact that OSCCs often are diagnosed at an advanced stage emphasizes the need for improving the COE, and the need to develop adjuncts to assist in oral mucosal lesion detection and diagnosis.”
LED Medical is the inventor and manufacturer of the VELscope Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. VELscope Vx devices are now used to conduct more screenings for oral cancer and other oral diseases than any other adjunctive device. To date, there have been more than 12,000 VELscope Vx systems sold globally and they have been used to perform more than 25 million exams.
According to Peter Whitehead, founder and CEO of LED Medical, “We certainly agree that the conventional clinical oral exam needs to be supplemented with an adjunctive screening device, which is why we collaborated with the British Columbia Cancer Agency to pioneer the application of tissue fluorescence visualization technology to the oral cavity. Moreover, we can unequivocally show through numerous studies and extensive real-world experience that our VELscope Vx is a highly effective adjunctive screening device that is also easy to use, comfortable and affordable for both dental practices and their patients.”
As an example, Mr. Whitehead cited a comprehensive independent study conducted by Dr. Edmund Truelove of the University of Washington. In this study of 620 routine dental patients, the VELscope Vx device detected 28 lesions that were not detected by a conventional clinical oral exam. Of these 28 lesions, five were dysplastic and potentially pre-cancerous.
In addition, Mr. Whitehead noted that an independent study of dental practices that use the VELscope Vx or earlier generation models showed consistently high satisfaction results with the technology and its performance. “When surveyed about the VELscope technology’s effectiveness in detecting cancerous or pre-cancerous lesions that would otherwise have been missed, we received overwhelmingly positive feedback,” stated Mr. Whitehead. “VELscope technology received high marks for patient comfort during screening, the speed and affordability of the screenings, the ability of the technology to detect anomalous tissue, and the ease of incorporation into the workflow of the dental practice. Many dentists also reported that their ability to offer VELscope Vx screenings helped them attract new patients and increase incremental revenues. Over 90 percent of dental professionals surveyed stated they would recommend the VELscope Vx to a colleague.”
About LED Medical Diagnostics Inc.
Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED-based visualization technologies for the medical industry. Through its wholly-owned subsidiary, LED Dental Inc., the company manufactures the VELscope Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. For more information, visit www.velscope.com.
For media or investor relations, please contact:
Mark Komonoski
Investor Relations
LedMedical Diagnostics Inc. (TSX.v: LMD)
--------------------------------------------------
Phone: (403) 255-8483
Toll-Free: (877) 255-8483
Cell: (403) 470-8384
E-Mail: mark@komonoski.com
Skype: mkomonoski
hammertime69
12 años hace
World Cancer Day: Eight Dental Practices in the
Seattle-Tacoma Area Install Oral Cancer Screening Devices
Representative of Oral Cancer Foundation (and oral cancer survivor) in attendance to raise
awareness of the prevalence of this disease and the importance of early detection.
SEATTLE-TACOMA, Washington – February 4, 2013 @ 5:30PM PST –LED Medical Diagnostics Inc. is pleased to announce that a team of Seattle-Tacoma dentists will receive training at Parkland Family Dentistry today, World Cancer Day (http://www.worldcancerday.org/), on how to use the VELscope Vx Enhanced Oral Assessment System, the first device cleared by the FDA to help dental and medical professionals discover oral cancer and pre-cancer that might not be visible to the naked eye.
Parkland Family Dentistry is located at 12165 Pacific Avenue in Tacoma, Washington. The training session begins at 5:30 pm. Seattle/Tacoma media are invited to attend this event, where they can interview and gather footage of the dentists as well as Eric Statler, a Stage 4 oral cancer survivor and spokesperson for the Oral Cancer Foundation.
Background
Tacoma residents Dr. Tom Henry and his wife Susie own eight dental practices in the Seattle-Tacoma area. In October, one month after Susie's brother was diagnosed with Stage 4 oral cancer, she and Dr. Henry attended a talk on oral cancer given by Eric Statler. The next month, sadly in an ironic twist, Susie was diagnosed with Stage 3 oral cancer. Soon thereafter, she and Dr. Henry asked their dental equipment supplier if there was a product that would help dentists detect oral cancer in early stages; their objective was to minimize the chances that any of their patients would ever be diagnosed with late stage oral cancer the way Susie and her brother had just been. The sales representative did her research, came back and recommended the VELscope Vx Enhanced Oral Assessment System. The Henrys ordered one system for each of their dental offices.
A VELscope Vx screening saves lives and is simple, non-invasive and takes minutes to perform.
A VELscope Vx screening takes only a few minutes and is very affordable and completely non-invasive for the patient. Given that one American dies of oral cancer every hour of every day, and that detecting the disease in early stages rather than late stages may be the difference between life and death, this is a story your viewers will want and need to see.
About LED Medical Diagnostics Inc.
Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED-based visualization technologies for the medical industry. Through its wholly-owned subsidiary, LED Dental Inc., the company manufactures the VELscope Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. VELscope Vx devices are now used worldwide to conduct more screenings for oral cancer and other oral diseases than any other adjunctive device. For more information, visit www.velscope.com.
Media Contact
Marc Hoelscher
Corporate Communications
LED Medical Diagnostics Inc. (TSX.v: LMD)
E-Mail: marc@hoelscher.ca
Mobile: 250.588.0182
Product Information
Ryan Desrochers
Sales Manager
Inside Territory Manager, USA
Phone: 1-888-541-4614 Ext 268
www.leddental.com
Investor Relations
Mark Komonoski
Investor Relations
LED Medical Diagnostics Inc. (TSX.V: LMD)
Telephone: 403.255-8483
Toll-free: 877.255-8483
Mobile: 403.470-8384
Email: mark@komonoski.com
hammertime69
12 años hace
LED Medical Diagnostics Begins Trading on OTCQX(R)
BURNABY, BRITISH COLUMBIA | NEW YORK, NY – February 26, 2013 – LED Medical Diagnostics Inc. (“LED Medical”, “the Company”), a developer of tissue visualization detection technologies for the medical industry, is pleased to announce that today it began trading on the OTCQX International (symbol: “LEDIF”), a segment of the OTCQX® marketplace reserved for high-quality, non-U.S. companies listed on a qualified stock exchange in their home country. U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
“We are pleased LED Medical Diagnostics Inc. has chosen to trade on OTCQX,” said R. Cromwell Coulson, President and CEO of OTC Markets Group. “OTCQX is the highest OTC marketplace offering qualifying companies like LED Medical Diagnostics the means to grow their U.S. shareholder base through high-quality disclosure, transparent trading and ease of access to company information.”
“We are proud to join OTCQX,” said Peter Whitehead, founder and CEO of LED Medical. “We are committed to providing our U.S. investors with timely news and information to help them better analyze, value and trade our securities.”
Brean Capital, LLC will serve as LED Medical Diagnostics’ Principal American Liaison (“PAL”) on OTCQX, responsible for providing professional guidance on OTCQX requirements.
Mark Komonoski
Investor Relations
LED Medical Diagnostics Inc. (TSX.v: LMD)
Toll-Free: (877) 255-8483
Cell: (403) 470-8384
mark@komonoski.com
Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Renee
4 años hace
syboman
8 años hace
growacet
8 años hace
OhManIDied
10 años hace
Hot Features
Premium
